Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2025-06-04 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
2025年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's 2025 second extraordinary shareholders' meeting. It includes details about the meeting date, location, attendance, voting results, and legal compliance. There is no financial data or detailed report content, only the voting results and meeting procedural information. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes rather than a full report or presentation.
2025-06-04 Chinese
浙江天册律师事务所关于浙江海昇药业股份有限公司2025年第二次临时股东会的法律意见书
Regulatory Filings
2025-06-04 Chinese
2024年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2024 annual equity distribution plan by Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the dividend distribution, stock bonus issuance, tax implications, record dates, and shareholding changes. The document is titled as an 'annual equity distribution implementation announcement' and includes specifics on dividend amounts and share capital changes. It does not contain full financial statements or comprehensive financial performance data, but rather focuses on dividend and share distribution details. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related shareholder details.
2025-05-28 Chinese
关于获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the approval of a chemical raw material drug listing application by the National Medical Products Administration. It includes details about the drug, approval number, registration standards, and the impact on the company. The document is short (974 characters) and serves as a formal notification of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed investor information. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-05-28 Chinese
2024年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 Annual General Meeting (AGM) of Zhejiang Haisheng Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including the annual report, financial statements, dividend distribution plan, amendments to the articles of association, and other corporate governance matters. The document is not the annual report itself but the official announcement of the voting results and decisions made at the AGM. The length is under 5,000 characters and it focuses on the meeting resolutions and voting outcomes, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-18 Chinese
长江证券承销保荐有限公司关于浙江海昇药业股份有限公司使用部分闲置募集资金进行现金管理的专项核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a securities underwriting and sponsorship company regarding the use of idle raised funds by Zhejiang Haisheng Pharmaceutical Co., Ltd. It includes specifics about the fundraising, usage progress, storage, investment decisions, risk controls, and the sponsor's opinion. The content focuses on the use of idle raised funds for cash management, with detailed financial figures and regulatory compliance references. It is not a brief announcement or a certification letter but a substantive report on the use of funds and related approvals. This fits the category of a Capital/Financing Update (CAP), as it deals with updates on the company's fundraising and capital usage activities.
2025-05-18 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.